小分子偶联药物结合小分子药物的灵活性与偶联技术的增效潜力，推动肿瘤治疗向高效低毒方向演进，成为偶联药物赛道中具潜力的分支。始于对传统化疗及抗体偶联药物（ADC）的优化探索，旨在通过精准递送提高疗效并降低系统毒性，在靶向性、安全性与成本等方面具备优势。

医药生物行业：触底反弹把握景气方向－2025年中期投资策略

医药生物行业：MNC账上还有多少钱？还有啥可能布局？【创新药大牛市】分支思路（一）中国超市更新

医药生物行业：IBD治疗领域存在未满足的需求，关注新靶点、新机制－创新药盘点系列报告

医药生物行业：2025ASCO大会国内重点研究总结报告

中国诸多创新药资产近年来逐步进入全球视野，临床数据在各类学术会议上占据越发重要的地位，BD授权金额及数 量持续攀升，全球影响力持续扩大。伴随着临床数据的驱动以及持续强化的BD预期的催化，创新药板块在25H1迎来一轮估值的修复，越来越多中国资产的全球价值开始获得认同。信达生物核心肿瘤管线资产IBI363（PD1/IL2α）在实体瘤上有望实现“热” 肿瘤超越+“冷”肿瘤突破，具备超重磅炸弹潜力。康方生物作为全球双抗引领者，其核心产品依沃西（AK112，PD-1/VEGF双 抗）成为全球首个在1L肺癌治疗中mPFS超越K药的双抗，具有成为新一代IO基石药物的巨大潜力。

全球山羊奶配方奶粉市场规模和份额分析——增长、趋势和预测（2025-2030年）

The market by value in this report is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography. • Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The graphics processing unit (GPU) is a type of computing technology that is designed for parallel processing and is used in a varied range of applications, such as graphics and video rendering. GPUs are also gaining traction across innovative production and artificial intelligence (AI). These units were initially designed to increase the speed of executing 3D graphics, and over time, they became flexible and programmable because of their enhanced capabilities, which allow graphics programmers to create interesting visual effects and realistic scenes with advanced lighting and shadowing techniques. Furthermore, other users also began to tap the power of GPUs to accelerate additional workloads in high-performance computing (HPC) and deep learning, among others.

软件与服务行业：AMD发布MI350系列产品，单卡和综合性能再次大幅提升－算力产业系列跟踪